AAAAAA

   
Results: 1-21 |
Results: 21
GLUCURONIDATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE (ZIDOVUDINE) BY HUMAN LIVER-MICROSOMES - RELEVANCE TO CLINICAL PHARMACOKINETIC INTERACTIONS WITH ATOVAQUONE, FLUCONAZOLE, METHADONE, AND VALPROIC ACID
Authors: TRAPNELL CB KLECKER RW JAMISDOW C COLLINS JM
Citation: Cb. Trapnell et al., GLUCURONIDATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE (ZIDOVUDINE) BY HUMAN LIVER-MICROSOMES - RELEVANCE TO CLINICAL PHARMACOKINETIC INTERACTIONS WITH ATOVAQUONE, FLUCONAZOLE, METHADONE, AND VALPROIC ACID, Antimicrobial agents and chemotherapy, 42(7), 1998, pp. 1592-1596
A PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE EFFECT OF RIFAMPIN AND RIFABUTIN ON COMBINATION ORAL-CONTRACEPTIVES
Authors: BARDITCHCROVO P TRAPNELL CB ETTE E ZACUR H FLEXNER C
Citation: P. Barditchcrovo et al., A PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE EFFECT OF RIFAMPIN AND RIFABUTIN ON COMBINATION ORAL-CONTRACEPTIVES, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 31-31
PREFACE TO THE 1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS/
Authors: MASUR H KAPLAN JE HOLMES KK BAKER AC BARR D BENSON C BROSGART C CHAISSON R COOPER E CRUMPACKER C DECKER C DREW L EISINGER R ELSADR W FREEDBERG K GOLDBERGER M GORDIN F GREAVES W GROSS P HAFNER R HAVLIR D HORSBURGH R JABS D KITAHATA M KOVACS J MARTONE W MAYERS D MELNICK D MOFENSON L NEATON J NELSON C OLDFIELD E PHAIR J POLIS M POLSKY B POWDERLY W RIMLAND D SLOAND E SOLOMON L SPECTOR S SPERLING R TRAPNELL CB VANDYKE R WHITLEY R WRIGHT T BELAY E BUTLER JC CASTRO KG DYKEWICZ C EDLIN BR ELLERBROCK T HAJJEH RA JAFFE HW JURANEK D MCNEIL M MILLER B PELLETT PE REEVES W SCHLUTER WW SPIEGEL RA STEWART JA STYRT B VERNON SD WARD J
Citation: H. Masur et al., PREFACE TO THE 1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS/, Clinical infectious diseases, 25, 1997, pp. 299
1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - DISEASE-SPECIFIC RECOMMENDATIONS/
Authors: MASUR H KAPLAN JE HOLMES KK ARMSTRONG D BAKER AC BARR D BENSON C BROSGART C CHAISSON R COOPER E CRUMPACKER C DECKER C DREW L EISINGER R ELSADR W FREEDBERG K GOLDBERGER M GORDIN F GREAVES W GROSS P HAFNER R HAVLIR D HORSBURGH R JABS D KITAHATA M KOVACS J MARTONE W MAYERS D MELNICK D MOFENSON L NEATON J NELSON C OLDFIELD E PHAIR J POLIS M POLSKY B POWDERLY W RIMLAND D SLOAND E SOLOMON L SPECTOR S SPERLING R TRAPNELL CB VANDYKE R WHITLEY R WRIGHT T BELAY E BUTLER JC CASTRO KG DYKEWICZ C EDLIN BR ELLERBROCK T HAJJEH RA JAFFE HW JURANEK D MCNEIL M MILLER B PELLETT PE REEVES W SCHLUTER WW SPIEGEL RA STEWART JA STYRT B VERNON SD WARD J
Citation: H. Masur et al., 1997 USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - DISEASE-SPECIFIC RECOMMENDATIONS/, Clinical infectious diseases, 25, 1997, pp. 313-335
METABOLISM OF RIFABUTIN AND ITS 25-DESACETYL METABOLITE, LM565, BY HUMAN LIVER-MICROSOMES AND RECOMBINANT HUMAN CYTOCHROME-P-450 3A4 - RELEVANCE TO CLINICAL INTERACTION WITH FLUCONAZOLE
Authors: TRAPNELL CB JAMISDOW C KLECKER RW COLLINS JM
Citation: Cb. Trapnell et al., METABOLISM OF RIFABUTIN AND ITS 25-DESACETYL METABOLITE, LM565, BY HUMAN LIVER-MICROSOMES AND RECOMBINANT HUMAN CYTOCHROME-P-450 3A4 - RELEVANCE TO CLINICAL INTERACTION WITH FLUCONAZOLE, Antimicrobial agents and chemotherapy, 41(5), 1997, pp. 924-926
QUANTITATION OF VAGINALLY ADMINISTERED NONOXYNOL-9 IN PREMENOPAUSAL WOMEN
Authors: BARDITCHCROVO P WITTER F HAMZEH F MCPHERSON J STRATTON P ALEXANDER NJ TRAPNELL CB
Citation: P. Barditchcrovo et al., QUANTITATION OF VAGINALLY ADMINISTERED NONOXYNOL-9 IN PREMENOPAUSAL WOMEN, Contraception, 55(4), 1997, pp. 261-263
THALIDOMIDE PHARMACOKINETICS DO NOT CHANGE WITH CHRONIC ADMINISTRATION
Authors: DONAHUE SR COLLINS JM FLOCKHART DA ABERNETHY DR TRAPNELL CB
Citation: Sr. Donahue et al., THALIDOMIDE PHARMACOKINETICS DO NOT CHANGE WITH CHRONIC ADMINISTRATION, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 89-89
EFFECT OF FOOD ON THE RELATIVE BIOAVAILABILITY OF ORAL GANCICLOVIR
Authors: LAVELLE J FOLLANSBEE S TRAPNELL CB BUHLES WC GRIFFY KG JUNG D DORR A CONNER J
Citation: J. Lavelle et al., EFFECT OF FOOD ON THE RELATIVE BIOAVAILABILITY OF ORAL GANCICLOVIR, Journal of clinical pharmacology, 36(3), 1996, pp. 238-241
PHARMACOKINETICS OF F105, A HUMAN MONOCLONAL-ANTIBODY, IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Authors: WOLFE EJ CAVACINI LA SAMORE MH POSNER MR KOZIAL C SPINO C TRAPNELL CB KETTER N HAMMER S GAMBERTOGLIO JG
Citation: Ej. Wolfe et al., PHARMACOKINETICS OF F105, A HUMAN MONOCLONAL-ANTIBODY, IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, Clinical pharmacology and therapeutics, 59(6), 1996, pp. 662-667
ALTERATION OF DAPSONE METABOLISM BY RIFABUTIN IN HIV(+) SUBJECTS
Authors: SALCEDO J NARANG PK SWEENY J BOONE S YOUNG M TRAPNELL CB
Citation: J. Salcedo et al., ALTERATION OF DAPSONE METABOLISM BY RIFABUTIN IN HIV(+) SUBJECTS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 3-3
SCREENING FOR BETA-OXIDATION ABNORMALITIES AS AN INDICATOR OF DRUG-INDUCED IMPAIRED MITOCHONDRIAL-FUNCTION IN PEOPLE RECEIVING ZIDOVUDINE (ZDV)
Authors: WACHSMAN M BARDITCHCROVO P PETTY BG TRAPNELL CB BRUSILOW S LIETMAN PS
Citation: M. Wachsman et al., SCREENING FOR BETA-OXIDATION ABNORMALITIES AS AN INDICATOR OF DRUG-INDUCED IMPAIRED MITOCHONDRIAL-FUNCTION IN PEOPLE RECEIVING ZIDOVUDINE (ZDV), Clinical pharmacology and therapeutics, 59(2), 1996, pp. 50-50
QUANTITATION OF VAGINALLY ADMINISTERED NONOXYNOL-9 (N9) IN PREMENOPAUSAL WOMEN
Authors: BARDITCHCROVO P WITTER F HAMZEH F MCPHERSON J STRATTON P ALEXANDER N TRAPNELL CB HOPKINS J
Citation: P. Barditchcrovo et al., QUANTITATION OF VAGINALLY ADMINISTERED NONOXYNOL-9 (N9) IN PREMENOPAUSAL WOMEN, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 97-97
WOMEN HAVE GREATER QTC PROLONGATION WITH QUINIDINE THAN MEN
Authors: BENTON RE SALE M CHEN YW TRAPNELL CB FLOCKHART DA WOOSLEY RL
Citation: Re. Benton et al., WOMEN HAVE GREATER QTC PROLONGATION WITH QUINIDINE THAN MEN, Circulation, 94(8), 1996, pp. 4314-4314
LACK OF BETA-OXIDATION DEFECTS IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS WITH AND WITHOUT CHRONIC ZIDOVUDINE EXPOSURE
Authors: WACHSMAN M BARDITCHCROVO P LIETMAN PS TRAPNELL CB
Citation: M. Wachsman et al., LACK OF BETA-OXIDATION DEFECTS IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS WITH AND WITHOUT CHRONIC ZIDOVUDINE EXPOSURE, Blood, 88(8), 1996, pp. 3243-3244
INCREASED PLASMA RIFABUTIN LEVELS WITH CONCOMITANT FLUCONAZOLE THERAPY IN HIV-INFECTED PATIENTS
Authors: TRAPNELL CB NARANG PK LI R LAVELLE JP
Citation: Cb. Trapnell et al., INCREASED PLASMA RIFABUTIN LEVELS WITH CONCOMITANT FLUCONAZOLE THERAPY IN HIV-INFECTED PATIENTS, Annals of internal medicine, 124(6), 1996, pp. 573-576
USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - INTRODUCTION/
Authors: KAPLAN JE MASUR H HOLMES KK MCNEIL MM SCHONBERGER LB NAVIN TR HANSON DL GROSS PA JAFFE HW LANIER D SCHRAM N COOPER E FREEDBERG KA MAYER K BLINKHORN R ELLNER J ANGULO F BERKELMAN R BREIMAN R BRYAN R BUEHLER J CLADWELL B CASTRO K CHILDS JE CHU S CIESIELSKI C DROTMAN DP EDLIN B ELLERBROCK T FLEMING P GEITER L HAJJEH R HANSON D HOLMBERG S HUGHES J JAFFE H JONES J JURANEK D KAPLAN JE KELLER D MARTONE W MILLER B NAVIN T NESLUND V OSTROFF S PELLETT PE PINNER R REEF S REEVES WC REGNERY R RICHARDS F ROGERS M SIMONDS RJ SIMONE P SMITH D SOLOMON S SPIEGEL R STEWART J SWERDLOW D VERNON S WARD J NEAL J SCHLECH W WILFERT C HORSBURGH R MCGOWAN J RIMLAND D GOLDBERGER M TRAPNELL CB BARR D TORRES G STETLER H GROSS P ELSADAR W COTTON D GREAVES W BARTLETT J CHAISSON R FEINBERG J QUINN T HORMAN J MACDONALD K WILSON M SPERLING R AVANDANO A BAKER AC KALICA A KOVACS J POLIS M SCHNITTMAN S NELSON C PHAIR J BENSON C WOOD B HUGHES W LUFT B HYSLOP N WHITLEY R AMPEL N DREW WL KOEHLER J WOFSY C
Citation: Je. Kaplan et al., USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - INTRODUCTION/, Clinical infectious diseases, 21, 1995, pp. 1-11
USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - AN OVERVIEW/
Authors: KAPLAN JE MASUR H HOLMES KK WILFERT CM SPERLING R BAKER SA TRAPNELL CB FREEDBERG KA COTTON D POWDERLY WG JAFFE HW LANIER D SCHRAM N COOPER E MAYER K BLINKHORN R ELLNER J ANGULO J BERKELMAN R BREIMAN R BRYAN R BEUHLER J CALDWELL B CASTRO K CHILDS JE CHU S CIESIELSKI C DROTMAN DP EDLIN B ELLERBROCK T FLEMING P GEITER L HAJJEH R HANSON D HOLMBERG S HUGHES J JAFFE H JONES J JURANEK D KELLER D MARTONE W MCNEIL MM MILLER B NAVIN T NESLUND V OSTROFF S PELLETT PE PINNER R REEF S REEVES WC REGNERY R RICHARDS F ROGERS M SCHONBERGER LB SIMONDS RJ SIMONE P SMITH D SOLOMON S SPIEGEL R STEWART J SWERDLOW D VERNON S WARD J NEAL J SCHLECH W WILFERT C HORSBURGH R MCGOWAN J RIMLAND D GOLDBERGER M BARR D TORRES G STETLER H GROSS P ELSADR W GREAVES W BARTLETT J CHAISON R FEINBERG J QUINN T HORMAN J MACDONALD K WILSON M AVANDANO A BAKER AC KALICA A KOVACS J POLIS M SCHNITTMAN S NELSON C PHAIR J BENSON C WOOD B HUGHES W LUFT B HYSLOP N WHITLEY R AMPEL N DREW WL KOEHLER J WOFSY C
Citation: Je. Kaplan et al., USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - AN OVERVIEW/, Clinical infectious diseases, 21, 1995, pp. 12-31
USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - DISEASE-SPECIFIC RECOMMENDATIONS/
Authors: KAPLAN JE MASUR H HOLMES KK LANIER D SCHRAM N COOPER E FREEDBERG KA MAYER K BLINKHORN R ELLNER J ANGULO F BERKELMAN R BREIMAN R BRYAN R BUEHLER J CALDWELL B CASTRO K CHILDS JE CHU S CIESIELSKI C DROTMAN DP EDLIN B ELLERBROCK T FLEMING P GEITER L HAJJEH R HANSON D HOLMBERG S HUGHES J JAFFE H JONES J JURANEK D KELLER D MARTONE W MCNEIL MM MILLER B NAVIN T NESLUND V OSTROFF S PELLETT PE PINNER R REEF S REEVES WC REGNERY R RICHARDS F ROGERS M SCHONBERGER LB SIMONDS RJ SIMONE P SMITH D SOLOMON S SPIEGEL R STEWART J SWERDLOW D VERNON S WARD J NEAL J SCHLECH W WILFERT C HORSBURGH R MCGOWAN J RIMLAND D GOLDBERGER M TRAPNELL CB BARR D TORRES G STETLER H GROSS P ELSADR W COTTON D GREAVES W BARTLETT J CHAISSON R FEINBERG J QUINN T HORMAN J MACDONALD K WILSON M SPERLING R AVANDANO A BAKER AC KALICA A KOVACS J POLIS M SCHNITTMAN S NELSON C PHAIR J BENSON C WOOD B HUGHES W LUFT B HYSLOP N WHITLEY R AMPEL N DREW WL KOEHLER J WOFSY C
Citation: Je. Kaplan et al., USPHS IDSA GUIDELINES FOR THE PREVENTION OF OPPORTUNISTIC INFECTIONS IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - DISEASE-SPECIFIC RECOMMENDATIONS/, Clinical infectious diseases, 21, 1995, pp. 32-43
A METABOLITE OF PENTAMIDINE BLOCKS HUMAN CARDIAC POTASSIUM CHANNELS
Authors: CHEN Y FLOCKHART DA TRAPNELL CB HALL JE SALCEDO J WOOSLEY RL
Citation: Y. Chen et al., A METABOLITE OF PENTAMIDINE BLOCKS HUMAN CARDIAC POTASSIUM CHANNELS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 194-194
FLUCONAZOLE AND ENHANCED EFFECT OF RIFABUTIN PROPHYLAXIS
Authors: NARANG PK TRAPNELL CB SCHOENFELDER JR LAVELLE JP BIANCHINE JR
Citation: Pk. Narang et al., FLUCONAZOLE AND ENHANCED EFFECT OF RIFABUTIN PROPHYLAXIS, The New England journal of medicine, 330(18), 1994, pp. 1316-1317
ALTERED DIDANOSINE PHARMACOKINETICS WITH CONCOMITANT ORAL GANCICLOVIR
Authors: TRAPNELL CB CIMOCH P GAINES K JUNG D HALE M LAVELLE J
Citation: Cb. Trapnell et al., ALTERED DIDANOSINE PHARMACOKINETICS WITH CONCOMITANT ORAL GANCICLOVIR, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 193-193
Risultati: 1-21 |